Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Respiratory Tract Diseases AND COPD AND placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    192 result(s) found for: Respiratory Tract Diseases AND COPD AND placebo. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-001800-39 Sponsor Protocol Number: D3251C00014 Start Date*: 2019-11-14
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to V...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003797-30 Sponsor Protocol Number: D9180C00003 Start Date*: 2022-01-31
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001053-16 Sponsor Protocol Number: D2550C00005 Start Date*: 2014-10-07
    Sponsor Name:AstraZeneca AB
    Full Title: A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Ma...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004166-16 Sponsor Protocol Number: SimvaCOPD Start Date*: 2012-08-07
    Sponsor Name:Abteilung für Pulmologie, Landesklinikum Thermenregion Hochegg
    Full Title: Does simvastatin treatment affect COPD exacerbations? - Evaluation in a randomized controlled trial
    Medical condition: patients with COPD in stage II-IV (according to the GOLD classification)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    14.1 10021881 - Infections and infestations 10029978 Obstructive chronic bronchitis with acute exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003510-41 Sponsor Protocol Number: 200163 Start Date*: 2014-01-24
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A two part, Phase IIa, randomized, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of oral danirixin (GSK1325756) in symp...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001363-67 Sponsor Protocol Number: D5241C00001 Start Date*: 2019-10-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients with Moderate to Very Severe Chronic Obstru...
    Medical condition: Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-005389-39 Sponsor Protocol Number: D2340C00011 Start Date*: 2012-03-12
    Sponsor Name:ASTRAZENECA
    Full Title: A phase-II, double-blind, placebo-controlled, randomised, parallelgroup, multi-centre study to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423 or twice d...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-005205-40 Sponsor Protocol Number: RPL554-CO-203 Start Date*: 2017-08-29
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase IIb, randomized, double blind, placebo controlled, dose ranging study to assess the effect of RPL554 in patients with moderate to severe COPD.
    Medical condition: moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) GB (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-004297-98 Sponsor Protocol Number: 117113 Start Date*: 2014-09-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study 117113: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients characterized by eosinophil level.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) GB (Completed) DK (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-008192-34 Sponsor Protocol Number: ERD-01-08/EP Start Date*: 2009-08-13
    Sponsor Name:EDMOND PHARMA S.R.L.
    Full Title: THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomized, double-blind, placebo-controlled, parallel group, multicenter...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038738 SOC
    9.1 10029978 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) CZ (Completed) FR (Completed) DK (Completed) SK (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019685-87 Sponsor Protocol Number: RO-2455-404-RD Start Date*: 2011-04-27
    Sponsor Name:Takeda Pharma A/S
    Full Title: Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 μg versus placebo
    Medical condition: severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) AT (Completed) DK (Completed) GR (Completed) NL (Completed) HU (Completed) SK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001818-38 Sponsor Protocol Number: EFC16750 Start Date*: 2021-03-02
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003373-10 Sponsor Protocol Number: M/34273/47 Start Date*: 2014-03-18
    Sponsor Name:ALMIRALL S.A.
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, 2 PERIOD CROSSOVER CLINICAL STUDY TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 ΜCG BID ON COPD SYMPTOMS AND SLEEP QUALITY AFTER 3 WEEKS OF TREATMENT IN PATIENT...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000053-21 Sponsor Protocol Number: FLUI-2014-134 Start Date*: 2015-05-05
    Sponsor Name:FLUIDDA nv
    Full Title: Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA/LAMA therapy using Functional Respiratory Imaging.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001805-18 Sponsor Protocol Number: Emera003 Start Date*: 2016-08-11
    Sponsor Name:NBMI Science AB
    Full Title: A randomised, placebo-controlled, blinded, cross-over, pilot study to explore safety and efficacy of NBMI treatment of patients with mild, moderate and severe Chronic Obstructive Pulmonary Disease ...
    Medical condition: Patients with Chronic Obstructive Pulmonary Disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003771-34 Sponsor Protocol Number: D9180C00004 Start Date*: 2022-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003675-21 Sponsor Protocol Number: 205724 Start Date*: 2017-06-01
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo ...
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) NL (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2013-004298-28 Sponsor Protocol Number: MEA117106 Start Date*: 2014-05-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Study MEA117106: Mepolizumab vs. Placebo as add-on treatment for frequently exacerbating COPD patients.
    Medical condition: Treatment of severe Chronic Obstructive Pulmonary Disease (COPD) in patients presenting frequent exacerbations
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) PL (Completed) IT (Completed) BE (Completed) ES (Completed) EE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002992-27 Sponsor Protocol Number: 201496 Start Date*: 2014-10-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: 201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects with Chronic Obstructive Pulmonary Disease (COPD).
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended) DE (Completed) BG (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000692-36 Sponsor Protocol Number: CCSJ117B12201 Start Date*: 2021-12-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-week, randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) DE (Completed) BE (Prematurely Ended) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 08:04:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA